CA3025208A1 - Compositions comprenant du cannabidiol et de l'acide hyaluronique pour le traitement de maladies inflammatoires des articulations - Google Patents

Compositions comprenant du cannabidiol et de l'acide hyaluronique pour le traitement de maladies inflammatoires des articulations Download PDF

Info

Publication number
CA3025208A1
CA3025208A1 CA3025208A CA3025208A CA3025208A1 CA 3025208 A1 CA3025208 A1 CA 3025208A1 CA 3025208 A CA3025208 A CA 3025208A CA 3025208 A CA3025208 A CA 3025208A CA 3025208 A1 CA3025208 A1 CA 3025208A1
Authority
CA
Canada
Prior art keywords
composition
cbd
hyaluronic acid
phosphatidylcholine
phospholipon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3025208A
Other languages
English (en)
Inventor
Tamir GEDO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bol Pharma Ltd
Original Assignee
Bol Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bol Pharma Ltd filed Critical Bol Pharma Ltd
Publication of CA3025208A1 publication Critical patent/CA3025208A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions comprenant une combinaison de cannabidiol (CBD) ou d'un dérivé de celui-ci, et d'acide hyaluronique ou d'un sel de celui-ci, un phospholipide, et éventuellement un support, des procédés d'utilisation des compositions pour traiter des maladies inflammatoires des articulations, ou une douleur ou une inflammation associée à de telles maladies, et des procédés pour les préparer.
CA3025208A 2016-05-24 2017-05-24 Compositions comprenant du cannabidiol et de l'acide hyaluronique pour le traitement de maladies inflammatoires des articulations Abandoned CA3025208A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662340576P 2016-05-24 2016-05-24
US62/340,576 2016-05-24
PCT/IL2017/050580 WO2017203529A1 (fr) 2016-05-24 2017-05-24 Compositions comprenant du cannabidiol et de l'acide hyaluronique pour le traitement de maladies inflammatoires des articulations

Publications (1)

Publication Number Publication Date
CA3025208A1 true CA3025208A1 (fr) 2017-11-30

Family

ID=60411168

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3025208A Abandoned CA3025208A1 (fr) 2016-05-24 2017-05-24 Compositions comprenant du cannabidiol et de l'acide hyaluronique pour le traitement de maladies inflammatoires des articulations

Country Status (4)

Country Link
EP (1) EP3463304A4 (fr)
CA (1) CA3025208A1 (fr)
IL (1) IL263174A (fr)
WO (1) WO2017203529A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022232897A1 (fr) * 2021-05-03 2022-11-10 Panag Pharma Inc. Compositions topiques de polyphénol de liposome pour le traitement et la prévention de divers troubles de la peau et leurs procédés de préparation
IT202200002000A1 (it) * 2022-02-04 2023-08-04 Mak Pharma S R L Composizione orale liposomiale di almeno un principio attivo scarsamente assorbibile a livello intestinale

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
AU2019299213A1 (en) * 2018-07-02 2021-02-11 Companion Sciences, Llc Cannabidiol combination compositions
WO2020021545A1 (fr) * 2018-07-25 2020-01-30 Bol Pharma Ltd. Cannabidiol et glucosamine pour le traitement de maladies articulaires inflammatoires
WO2020024056A1 (fr) * 2018-08-01 2020-02-06 Lazar Eve Compositions comprenant des cannabinoïdes et matériau absorbable et utilisations associées
KR20210116432A (ko) * 2018-10-10 2021-09-27 틸레이, 인크. 화학요법으로 유발된 메스꺼움 및 구토 치료를 위한 방법 및 제형
CA3119037A1 (fr) * 2018-12-11 2020-06-18 Disruption Labs Inc. Compositions pour l'administration d'agents therapeutiques et leurs methodes d'utilisation et leurs procedes de preparation
US20220054532A1 (en) * 2019-03-05 2022-02-24 Colleen Smith Veterinary compositions and methods of use therefor
KR20210151816A (ko) 2019-03-12 2021-12-14 이피엠 (아이피), 인코포레이티드 칸나비노이드 산 에스테르 조성물 및 이의 용도
US20200352849A1 (en) * 2019-05-07 2020-11-12 Adam M. Rotunda Topical Skin Formulations and Wound Care Products with Integrated CBD Delivery Mechanisms for Skin Rejuvenation, Wound Care and Healing, Pain and Itch Relief, and Scar Prevention and Treatment
IT201900008409A1 (it) * 2019-06-07 2020-12-07 Vivatis Pharma Gmbh Individuazione e selezione di un materiale di partenza vegetale di condroitina solfato e acido ialuronico vegetali, e trasformazione di tale materiale di partenza vegetale per l’ottenimento di ingredienti per utilizzo in alimenti, integratori, dispositivi medici o farmaci
JP7770688B2 (ja) * 2019-10-03 2025-11-17 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド リポソームカンナビノイドおよびその使用
WO2021091905A1 (fr) * 2019-11-08 2021-05-14 Vella Bioscience, Inc. Formulations liposomales pour l'administration de cannabinoïdes et leurs procédés de fabrication
US20230010871A1 (en) * 2019-12-13 2023-01-12 Folium Labs Inc. Complexes comprising a carbohydrate polymer and an active ingredient and processes for their preparation
GB201918846D0 (en) * 2019-12-19 2020-02-05 Gw Res Ltd Oral cannabinoid formulations
EP3861996A1 (fr) 2020-02-04 2021-08-11 I+Med S. Coop. Système de libération contrôlée de formulations de phytocannabinoïdes solubles dans un milieu aqueux, procédés et utilisations associés
CN112138138B (zh) * 2020-11-19 2023-05-23 乐康珍泰（天津）生物技术有限公司 一种用于治疗痛风的药物组合物及其制备方法
WO2022232574A1 (fr) 2021-04-29 2022-11-03 Tilray, Inc. Formulations dans lesquelles le cannabidiol est le constituant dominant, leurs procédés de fabrication et leurs utilisations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128326A (en) * 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US10004684B2 (en) * 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
DK2176208T3 (en) * 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
US20110142914A1 (en) * 2007-12-06 2011-06-16 Cytotech Labs, Llc Inhalable compositions having enhanced bioavailability
TWI382841B (zh) * 2010-10-29 2013-01-21 Univ China Medical 用於抑制發炎之醫藥組合物
US20130184354A1 (en) * 2012-01-13 2013-07-18 Donna K. Jackson Silicone and Hylauronic Acid (HLA) Delivery Systems for Products by Sustainable Processes for Medical Uses Including Wound Management
WO2013114377A1 (fr) * 2012-02-02 2013-08-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd Liposomes stables pour l'administration de médicament
RU2677658C2 (ru) * 2012-07-05 2019-01-18 Тайвэн Липосом Ко, Лтд. Способы лечения артрита
CA2929280A1 (fr) * 2013-10-31 2015-05-14 Full Spectrum Laboratories, Ltd. Formulations de terpene et de cannabinoides

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022232897A1 (fr) * 2021-05-03 2022-11-10 Panag Pharma Inc. Compositions topiques de polyphénol de liposome pour le traitement et la prévention de divers troubles de la peau et leurs procédés de préparation
IT202200002000A1 (it) * 2022-02-04 2023-08-04 Mak Pharma S R L Composizione orale liposomiale di almeno un principio attivo scarsamente assorbibile a livello intestinale

Also Published As

Publication number Publication date
EP3463304A1 (fr) 2019-04-10
WO2017203529A1 (fr) 2017-11-30
IL263174A (en) 2018-12-31
EP3463304A4 (fr) 2020-01-08

Similar Documents

Publication Publication Date Title
CA3025208A1 (fr) Compositions comprenant du cannabidiol et de l'acide hyaluronique pour le traitement de maladies inflammatoires des articulations
KR102055937B1 (ko) 불용성 코르티코스테로이드 및 수용성 코르티코스테로이드를 포함하는 약학적 제형
EP2916817B1 (fr) Formulations de capsaïcinoïde à base aqueuse et procédés de fabrication et d'utilisation
AU2014204739B2 (en) Compositions and methods for treating severe pain
CA3113462A1 (fr) Formulations de reproxalap pour le traitement du syndrome de l'oeil sec
KR102251124B1 (ko) 수계 캡사이시노이드 제형 및 제조방법 및 용도
SK11193A3 (en) Formulations containing hyaluronic acid
JP2019510824A (ja) 送達システム
JPH09512797A (ja) 癌の治療および転移の予防
AU2016209332B2 (en) Pharmaceutical formulation
JP2020189870A (ja) 関節を治療するための組成物及びキット
WO2020021545A1 (fr) Cannabidiol et glucosamine pour le traitement de maladies articulaires inflammatoires
JP7042262B2 (ja) 緑内障の治療のための、リポソームによって担持されるシチコリンを含む眼科用処方
CN113274343B (zh) 多元醇作为助溶剂在秋水仙碱外用组合物中的应用
US10300017B2 (en) Method and composition for treating cystitis
KR20120061841A (ko) 동통 억제용 의약 조성물
US20200121616A1 (en) Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
JP5681472B2 (ja) 眼科用組成物
Battaglia et al. Repurposing of parenterally administered active substances used to treat pain both systemically and locally
US20070142326A1 (en) Treatment of a condition in a mammal with administration of aminosugar and uses thereof
KR20090046839A (ko) 안구 적용용 아마인 추출물 약제
CA2540586A1 (fr) Traitement d'un trouble chez un mammifere par administration d'une sucre amine et utilisations associees
JP2021532074A (ja) 関節内ステロイドの合併症を軽減する方法
KR20140138640A (ko) 비강내 졸피뎀 투여용 치료 조성물
CN101152147B (zh) 一种川芎嗪类化合物乳剂及其制备方法

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20221125